Photodynamic Therapy in Occult-Only Lesions (POOL)

Novartis

Status and phase: Completed; Phase 4

Conditions: Age-Related Macular Degeneration

Treatments: Drug: Verteporfin for injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT00135837

CBPD952B2401

Details and patient eligibility

About

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 50 years or older
• Must see better or equal to 34 letters (visual acuity)
• Choroidal neovascularization (CNV) lesion must be occult only

Exclusion criteria

• Evidence of classic CNV in the lesion
• Prior treatment of disease in study eye
• Have a history of moderate to severe hepatic impairment

Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)